deferasirox:
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Transfusional Hemosiderosis
Conditions
Transfusional Hemosiderosis
Trial Timeline
May 1, 2009 โ Aug 1, 2010
NCT ID
NCT00845871About deferasirox:
deferasirox: is a approved stage product being developed by Novartis for Transfusional Hemosiderosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00845871. Target conditions include Transfusional Hemosiderosis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00845871 | Approved | Completed |
Competing Products
6 competing products in Transfusional Hemosiderosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Deferasirox | Novartis | Phase 2 | 52 |
| ICL670 | Novartis | Phase 2 | 52 |
| deferasirox | Novartis | Pre-clinical | 23 |
| Deferasirox | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Phase 3 | 77 |
| Core Study: Deferasirox + Core Study: Deferoxamine + Extension: deferoxamine to deferasirox + Extension: deferasirox to deferoxamine + Deferasirox + Deferoxamine | Novartis | Phase 2 | 52 |